EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team

EBMT 2025 | Prof. Xiaoxia Hu: Focusing on Comprehensive Leukemia Management and Key Findings from the Ruijin Transplant Team

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a cornerstone in the treatment of various hematologic diseases. However, several peri-transplant challenges persist, particularly regarding the optimal timing of transplantation, the role of consolidation therapy, and maintenance strategies. At the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025), the transplant team from Ruijin Hospital, Shanghai JiaoTong University School of Medicine, presented several notable studies. Among them, three studies—B254, B259, and A001—focused on comprehensive leukemia management and transplant integration, drawing significant attention from the clinical community. Hematology Frontier invited Prof. Xiaoxia Hu to provide in-depth commentary on these research findings.
EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

EAU 2025 | Dr. Jeffrey S. Damrauer Shares Insights on Bladder Cancer Classification and Treatment

Bladder cancer is a biologically heterogeneous disease, and its classification plays a critical role in guiding treatment. However, current bladder cancer classification remains based primarily on clinical-pathological features or staging, with molecular subtyping yet to be standardized. At the 2025 European Association of Urology (EAU) Congress, Dr. Jeffrey S. Damrauer from the UNC Lineberger Comprehensive Cancer Center shared key insights on the response of different bladder cancer types to treatment, the role of neoadjuvant therapy, and the growing possibilities of bladder-sparing strategies.
Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

The 19th St. Gallen Breast Cancer Conference (SGBCC), held in Vienna from March 12 to 15, 2025, remains one of the most influential global platforms in early breast cancer care. Among seven studies awarded the prestigious Best Poster Award, four came from China, including a multi-center real-world study led by Professor Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences. Her research focused on treatment-insensitive HER2-positive breast cancer patients undergoing neoadjuvant therapy. Oncology Frontier spoke with Professor Fan to learn more about the study’s results, and broader implications.